ADMA Biologics director granted RSUs and options

ADMA Biologics director Young Kwon reported new equity awards.

Rhea-AI Filing Summary

ADMA Biologics director Young Kwon reported new equity awards. On February 9, 2026, he received 10,690 shares of common stock in the form of restricted stock units granted at $0, which vest in two equal installments over one year, subject to continued service. He also received a stock option to buy 17,730 shares of common stock at an exercise price of $16.37 per share, vesting in twelve equal monthly installments and becoming fully vested on February 9, 2027. After these awards, he directly holds 263,020 shares of common stock, including RSUs, and 17,730 stock options.

Insider Trade Summary

Grant/Award: 28,420 shares

Grant/Award 2 txns

Insider KWON YOUNG

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,730	$0.00	$0.00
Grant/Award	Common Stock	10,690	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 17,730 contracts (Direct); Common Stock — 263,020 shares (Direct)

Footnotes (3)

1. F1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
2. F2. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 246,885 shares of common stock owned by the Reporting Person.
3. F3. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADMA (ADMA) report for Young Kwon?

ADMA Biologics reported that director Young Kwon received equity awards on February 9, 2026. He was granted 10,690 restricted stock units and a stock option for 17,730 shares, both subject to time-based vesting and continued service conditions.

How many restricted stock units did Young Kwon receive from ADMA (ADMA)?

Young Kwon received 10,690 restricted stock units from ADMA Biologics on February 9, 2026. These RSUs vest in two equal installments at six and 12 months after the grant date, becoming fully vested one year after grant if he continues to serve.

What are the terms of Young Kwon’s stock options at ADMA (ADMA)?

Young Kwon received a stock option covering 17,730 shares of ADMA Biologics common stock with a $16.37 exercise price. The options vest in twelve equal monthly installments and become fully vested on the one-year anniversary of the grant date, subject to continued service.

How many ADMA (ADMA) shares does Young Kwon own after this Form 4?

After the reported transactions, Young Kwon beneficially owns 263,020 shares of ADMA Biologics common stock directly, including restricted stock units. He also holds 17,730 stock options, providing additional potential future ownership if exercised.

Are Young Kwon’s new ADMA (ADMA) equity awards subject to vesting conditions?

Yes, both awards are time-based. The 10,690 RSUs vest in two equal installments over one year, while the 17,730 stock options vest in twelve equal monthly installments, with full vesting after one year, each requiring continued service.

Did Young Kwon buy or sell ADMA (ADMA) shares for cash in this filing?

No cash purchase or sale occurred in this Form 4. The filing reports grants of restricted stock units and stock options at a grant price of $0, representing equity compensation rather than open-market transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KWON YOUNG

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		10,690(1)	A	$0	263,020(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.37	02/09/2026		A		17,730		(3)	02/09/2036	Common Stock	17,730	$0	17,730	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

2. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 246,885 shares of common stock owned by the Reporting Person.

3. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

	/s/ Young Kwon, by Michael A. Goldstein as Attorney-in-fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.